How it Works

Daratumumab and hyaluronidase is a targeted monoclonal antibody that helps slow or stop the progression of multiple myeloma in several ways. 

• By attaching itself to multiple myeloma cells in the body, specifically to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, allowing your immune system to destroy them.
• By blocking cell growth or other functions necessary for cell growth.
• The subcutaneous version also has Hyaluronidase, whose main objective is to break down the skin tissue, allowing the Daratumumab's absorption.

How it’s Administered

Subcutaneous injection with a dosage of 1,800 mg / 30,000 units of hyaluronidase.

Who Should Take Darzalex Faspro (Daratumumab and Hyaluronidase)

Darzalex  Faspro  is currently approved for:

• Patients with a new diagnosis of multiple myeloma
• Patients with one or more prior multiple myeloma treatment

Who Shouldn’t Take Darzalex Faspro (Daratumumab and Hyaluronidase)

• Patients with a history of a severe allergic reaction to daratumumab, hyaluronidase,  or any of the ingredients in Darzalex Faspro
• Patients who are pregnant or plan to become pregnant for at least three months after the last dose
• Patients using Darzalex Faspro (Daratumumab and Hyaluronidase) should not breastfeed. It is not known if the drug passes into your breast milk

The Most Common Side Effects of Taking Darzalex Include: 

• Fatigue
• Nausea, constipation, and/or diarrhea
• Vomiting
• Muscle spasms
• Joint pain
• Back pain
• Shortness of breath 
• Fever 
• Chills
• Dizziness
• Trouble sleeping
• Cough and cold-like symptoms
• Increased risk of infection (principally upper respiratory infections)
• Nerve damage causing tingling, numbness or pain (Peripheral neuropathy)
• Swollen hands, ankles, or feet (Peripheral edema)

Daratumumab (IV) vs Daratumumab+Hyaluronidase (SC): 

The American Society of Clinical Oncology published a study in which they compared Darzalex Faspro® (SC) vs Darzalex® (IV) they gave one half the IV treatment and the other half had the SC. In which they found the following results:

• The IV drug showed a 37% response, and the SC showed a 41%, which showed they both are “essentially equivalent to each other.”
• The side effects related to the infusion (fever, chills, cough, shortness of breath) mainly were mild to moderate and appeared in some patients and mostly only with the 1st or 2nd dose, in the 34% of them using Daratumumab (IV) vs. the 12% of them using Daratumumab+hyaluronidase (Darzalex Faspro®).

Commonly Used With 

• Lenalidomide and dexamethasone 
• Bortezomib, melphalan, and prednisone
• Bortezomib and dexamethasone 
• Carfilzomib and dexamethasone 
• Pomalidomide and dexamethasone 
• Ixazomib 

Currently Being Tested With

• Steroids: Dexamethasone
• Immunomodulators agents: Lenalidomide, Pomalidomide
• CeLMOD: Iberdomide
• Proteasome inhibitors: Bortezomib, Carfilzomib, Ixazomib

Learn more about your treatments in Cure Hub